Otomagnetics LLC

Otomagnetics LLC develops innovative magnetic drug delivery systems for non-invasive treatments targeting the inner ear, middle ear, and ocular conditions, enhancing therapeutic outcomes through advanced technology. Otomagnetics LLC specializes in magnetic drug delivery systems, facilitating non-invasive treatments for various health conditions. The company is headquartered in Rockville, US. Abhita Vohra serves as the CEO.

In July 2017, the company raised USD 0. 10 mn in a Seed funding round from the Maryland Technology Development Corporation. The total amount raised by Otomagnetics is USD 0. 10 mn.

Otomagnetics, Inc. specializes in a proprietary magnetic injection system designed to deliver therapeutic payloads non-invasively to inner and middle ear compartments, the eye, and into the skin. The technology addresses crucial therapeutic delivery challenges, particularly for diseases of the inner ear, where traditional drug administration is hindered by the blood-labyrinth barrier. By facilitating drug delivery to the inner ear and middle ear without requiring eardrum puncture, Otomagnetics aims to improve treatment outcomes for conditions affecting these areas.

The company’s innovations may also extend to ocular therapies, offering a needle-free alternative for eye treatments in future applications. The primary customers and end users include healthcare providers and patients requiring advanced treatment options in otology and ophthalmology, with potential markets extending across North America and Europe. Otomagnetics operates on a transaction model that involves partnerships with healthcare institutions, directly serving clinics and hospitals as primary clients for its magnetic drug delivery system. The revenue structure includes business-to-business engagements, where healthcare providers utilize Otomagnetics' technology in patient care settings.

Specific products developed by the company, possibly including trademarked devices or services related to magnetic drug delivery, serve as the focal points for these transactions. While exact pricing details for these offerings are not disclosed, the revenue generation strategy is linked to contractual agreements that facilitate the integration of their technology into clinical practices. Otomagnetics plans to expand its product offerings and is currently working on new innovations in its magnetic drug delivery system to be launched in the near future. The company aims to penetrate new markets in North America and Europe, with targeted initiatives expected by the end of 2022.

The recent Seed funding of USD 0. 10 mn will support these developments, allowing Otomagnetics to enhance its technology and broaden its market reach.